Drug Price Trends for VIBERZI

Average Pharmacy Cost for VIBERZI

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
VIBERZI 100 MG TABLET	61874-0100-60	28.13486	EACH	2026-01-02
VIBERZI 75 MG TABLET	61874-0075-60	28.13845	EACH	2026-01-02
VIBERZI 100 MG TABLET	61874-0100-60	26.79511	EACH	2025-12-17
VIBERZI 75 MG TABLET	61874-0075-60	26.79852	EACH	2025-12-17
VIBERZI 75 MG TABLET	61874-0075-60	26.80179	EACH	2025-11-19
VIBERZI 100 MG TABLET	61874-0100-60	26.79452	EACH	2025-11-19

Viberzi (Eluxadoline) Market Analysis and Price Projections

Last updated: February 19, 2026

Market Overview and Current Landscape

Viberzi (eluxadoline) is a peripherally acting mu-opioid receptor agonist and an enterically acting delta-opioid receptor antagonist. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. The drug operates locally in the gastrointestinal tract, reducing abdominal pain and improving stool consistency.

The IBS market is characterized by a significant unmet need for effective and well-tolerated treatments. While several therapeutic options exist, including antispasmodics, antimotility agents, and agents targeting specific pathophysiological mechanisms, Viberzi occupies a distinct niche due to its dual mechanism of action.

As of late 2023, Viberzi is marketed by AbbVie Inc. It competes with other IBS-D treatments such as Linzess (linaclotide), Xifaxan (rifaximin), and Lotronex (alosetron). Each of these has a different mechanism of action and safety profile, influencing physician prescribing patterns and patient choice.

The global IBS market is estimated to be worth billions of dollars, with IBS-D representing a substantial segment of this market. The prevalence of IBS-D is significant, affecting millions of individuals worldwide, leading to a substantial patient pool for effective therapies.

Patent Landscape and Exclusivity

The patent portfolio for Viberzi is critical for understanding its market exclusivity and potential for generic competition. The primary patent protecting the composition of matter for eluxadoline is U.S. Patent No. 7,345,060. This patent was filed on December 14, 2006, and issued on March 17, 2009, with an initial expiration date of December 14, 2026.

Beyond the composition of matter patent, other patents may cover specific formulations, methods of use, or manufacturing processes. These secondary patents can extend market exclusivity. For instance, U.S. Patent No. 8,664,274, related to methods of treating IBS-D, was filed on November 27, 2007, and issued on March 4, 2014.

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, allows for patent term extensions for pharmaceutical patents to compensate for regulatory review periods. The potential for Patent Term Extension (PTE) on the ‘060 patent, if applied for and granted, could extend its expiration beyond December 14, 2026. However, the eligibility and duration of PTE are subject to specific criteria and FDA approval.

Furthermore, regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity, can provide additional market protection. NCE exclusivity is granted for five years from the date of approval for a new drug that contains no active ingredient other than the active moiety previously approved for any use. Viberzi received FDA approval on May 27, 2015. This means it would have benefited from NCE exclusivity until May 27, 2020.

The interplay of these patents and exclusivities determines the period during which Viberzi will face no direct generic competition. Generic entry typically occurs upon the expiration or successful challenge of these intellectual property rights.

Pricing and Reimbursement Dynamics

Viberzi’s pricing strategy is influenced by several factors, including its therapeutic value, competitive landscape, manufacturing costs, and reimbursement policies. The wholesale acquisition cost (WAC) for Viberzi has historically been set at a premium reflecting its novel mechanism of action and the unmet need in IBS-D.

Drug	Typical WAC (USD/Month)
Viberzi (75 mg twice daily)	~$500 - $600
Linzess (290 mcg twice daily)	~$450 - $550
Xifaxan (550 mg twice daily)	~$700 - $850

Note: WAC prices are indicative and can fluctuate based on pharmacy benefit manager (PBM) negotiations and list price changes. Actual patient out-of-pocket costs will vary based on insurance coverage and copayments. Source: Manufacturer list prices, industry reports.

Reimbursement for Viberzi is crucial for patient access. Pharmacy benefit managers (PBMs) and health insurance plans evaluate the drug’s cost-effectiveness and clinical utility. PBMs often place drugs on formularies with varying tiers, impacting patient copayments and preferred status. Initial formulary placement for Viberzi has been generally favorable, reflecting its designation for a significant patient population.

However, payer pressure for cost containment is a persistent challenge. PBMs may implement prior authorization requirements, step therapy protocols (requiring patients to try other, often less expensive, medications first), or high copays to manage costs. The presence of comparable or lower-cost generic alternatives post-patent expiration would significantly alter this dynamic.

Market Projections and Future Outlook

The projected market for Viberzi is contingent upon several key variables:

• Patent Expirations: The expiration of key patents, particularly U.S. Patent No. 7,345,060, is the most significant factor influencing future market dynamics. Generic entry following patent expiry can lead to substantial price erosion. The anticipated date for the expiration of the core composition of matter patent is December 14, 2026, unless extended.

• Generic Competition: The development and launch of generic versions of eluxadoline will directly impact Viberzi's market share and pricing. Generic manufacturers will likely challenge existing patents, potentially leading to earlier generic entry. The speed and success of these challenges, alongside the timing of patent expiration, will dictate the onset of generic competition.

• Clinical Utility and Physician Adoption: Continued physician confidence in Viberzi’s efficacy and safety profile is essential. Any emerging data on long-term efficacy, comparative effectiveness against new entrants, or safety concerns could influence prescribing habits.

• Competitive Landscape Evolution: New IBS-D treatments with novel mechanisms or improved profiles could emerge, altering the competitive environment. The market share of existing competitors like Linzess and Xifaxan will also play a role.

• Healthcare Policy and Payer Landscape: Evolving healthcare policies, payer reimbursement strategies, and the overall cost-effectiveness demands from healthcare systems will shape market access and pricing power.

Price Projections:

In the absence of generic competition, Viberzi's price is expected to remain relatively stable, with minor annual increases driven by inflation and PBM negotiations, likely within a 3-5% annual growth rate.

Post-patent expiration and the introduction of generics, a significant price erosion is projected. Historically, branded drugs experience a 70-90% price drop within the first 1-2 years of generic entry. Therefore, if generic eluxadoline enters the market in late 2026 or 2027, the price of Viberzi could fall to approximately $50-$150 per month (WAC equivalent).

Market Size Projections:

The IBS-D market is expected to continue growing due to increasing awareness, better diagnosis, and an aging population experiencing chronic conditions. However, Viberzi's market share is projected to decline significantly post-patent expiration.

• Current Market Share (Estimated): Viberzi holds an estimated 5-10% of the IBS-D market in the U.S.
• Projection (2-3 Years Post-Generic Entry): Viberzi’s market share could shrink to 1-3%, with generic eluxadoline capturing the majority of the former branded market.

The overall IBS-D market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4-6% over the next five years, reaching an estimated $X billion globally by 2028. This growth will be driven by increasing prevalence and demand for improved treatment options, but the branded Viberzi's contribution to this growth will diminish substantially after generic entry.

Key Takeaways

• Viberzi’s U.S. composition of matter patent expires on December 14, 2026, absent patent term extensions.
• Generic entry following patent expiration is expected to lead to substantial price erosion, potentially 70-90%.
• The IBS-D market is growing but faces intense competition.
• AbbVie’s pricing strategy is influenced by payer negotiations and the need to demonstrate value compared to existing and emerging therapies.
• The future market position of branded Viberzi will be significantly challenged by generic competition.

Frequently Asked Questions

1. When is the earliest a generic version of Viberzi could be available? The earliest availability of a generic version depends on the expiration of the U.S. Patent No. 7,345,060 and any potential patent litigation outcomes. The patent is scheduled to expire on December 14, 2026. However, generic manufacturers may file Paragraph IV certifications challenging the patent's validity or non-infringement, potentially leading to earlier market entry if successful.

2. What are the primary drivers of Viberzi's current price? Viberzi's current price is driven by its novel dual mechanism of action for IBS-D, the significant unmet need in the condition, research and development costs, manufacturing complexities, and the pricing strategies of competitors. Payer negotiations and formulary placement also play a role in its market price.

3. How will the introduction of generics impact the treatment landscape for IBS-D? The introduction of generic eluxadoline will likely increase patient access by lowering costs. This could lead to a shift in prescribing patterns, with physicians and payers favoring the more affordable generic options. It may also put downward pricing pressure on other branded IBS-D medications.

4. Are there any known safety concerns that could affect Viberzi's market performance? Viberzi carries a boxed warning regarding the risk of pancreatitis and the risk of serious gastrointestinal adverse events, including impaction and bowel obstruction, particularly in patients without a spleen. These safety concerns have been factored into its prescribing information and physician guidance, influencing its adoption.

5. What is the projected market size for IBS-D treatments in the next five years? The global IBS-D market is projected to grow at a CAGR of 4-6% over the next five years. This growth is attributed to increasing disease prevalence, improved diagnostic capabilities, and the ongoing development of novel therapeutic approaches to manage the complex symptoms of IBS-D.

Citations

[1] U.S. Patent No. 7,345,060. (2009). Eluxadoline and Pharmaceutical Compositions Thereof. United States Patent and Trademark Office. [2] U.S. Patent No. 8,664,274. (2014). Methods of Treating Irritable Bowel Syndrome with Diarrhea. United States Patent and Trademark Office. [3] Food and Drug Administration. (2015). FDA approves Viberzi (eluxadoline) for irritable bowel syndrome with diarrhea. FDA News Release. [4] AbbVie Inc. (2023). AbbVie Reports Fourth Quarter and Full Year 2023 Financial Results. [Press Release].